Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to a flow-wrap pack for wet wipes. The flow-wrap pack has a film defining a front wall and a back wall, a longitudinal sealed seam in the form of a fin seal and two transverse sealed seams defining a product space. The fin seal has an extended length and lies essentially flat against the back wall of the wrap pack, thereby covering a scored tear line and a resealable strip, said strip extending between the transverse sealed seams at an essentially right angle to the transverse sealed seams.

Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Abstract: A system including temperature measuring devices, a controller, and an actuator, maintains a desired gas temperature range in the secondary combustor by proportionally making adjustments to the primary air orifice or other primary air valve of a cordwood burning appliance. Heat output of the appliance is directly related to the temperature of the gases in the secondary combustor, and sufficient engagement of the second combustor during off-gassing of volatiles from the wood will control emissions from the appliance. The operator can select a desired room temperature via the thermostat and the controller will use different secondary gas temperature target ranges in order to meet the desired room temperature as commanded by the thermostat throughout the burn event. The controller also controls the start-up phase of combustion and charcoal phase of combustion.

Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. These compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Abstract: The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Abstract: The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.

Abstract: The devices and methods of placement of such devices disclosed herein are directed to altering gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having Chronic Obstructive Pulmonary Disease. More particularly, these devices produce and maintain collateral openings or channels through the airway wall so that oxygen depleted/carbon dioxide rich air is able to pass directly out of the lung tissue to facilitate both the exchange of oxygen ultimately into the blood and/or to decompress hyper-inflated lungs. The medical kits disclosed herein are also directed to produce and maintain collateral openings through airway walls.

Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

Abstract: The devices and methods of placement of such devices disclosed herein are directed to altering gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having Chronic Obstructive Pulmonary Disease. More particularly, these devices produce and maintain collateral openings or channels through the airway wall so that oxygen depleted/carbon dioxide rich air is able to pass directly out of the lung tissue to facilitate both the exchange of oxygen ultimately into the blood and/or to decompress hyper-inflated lungs. The medical kits disclosed herein are also directed to produce and maintain collateral openings through airway walls.

Abstract: The present invention is a suture device generally intended for use in puncture wounds of a body cavity. The suture device can be inserted through the tissue layer into the body cavity and extend needles attached to a common suture line, under endoscopic vision, for engagement with the internal side of the tissue layer. The needles are deployed using a straight spring that deforms outwardly from the shaft of the suture device when a force is applied to the spring. Because of the inherent characteristics of the spring, it bends perpendicular to the shaft of the suture device and the removably attached needle is moved outwardly while staying generally parallel to the shaft of the suture device. Once the force is removed on the spring, the spring returns to its original position close to the body of the shaft.

Abstract: The present invention is a suture device generally intended for use in puncture wounds of a body cavity. The suture device can be inserted through the tissue layer into the body cavity and extend needles attached to a common suture line, under endoscopic vision, for engagement with the internal side of the tissue layer. The needles are deployed using a straight spring that deforms outwardly from the shaft of the suture device when a force is applied to the spring. Because of the inherent characteristics of the spring, it bends perpendicular to the shaft of the suture device and the removably attached needle is moved outwardly while staying generally parallel to the shaft of the suture device. Once the force is removed on the spring, the spring returns to its original position close to the body of the shaft.

Abstract: The methods and devices disclosed altering gaseous flow within a lung to improve the expiration cycle of individuals having Chronic Obstructive Pulmonary Disease.